Foralumab - Tiziana Life Sciences

Drug Profile

Foralumab - Tiziana Life Sciences

Alternative Names: NI-0401; NI-0401/α-CD3; TZLS-401

Latest Information Update: 03 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medarex; NovImmune SA
  • Developer Harvard Medical School; NovImmune SA; Tiziana Life Sciences
  • Class Anti-inflammatories; Hepatoprotectants; Monoclonal antibodies
  • Mechanism of Action CD3 antigen inhibitors; Immunomodulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease
  • Phase I Primary biliary cirrhosis
  • Preclinical Inflammatory bowel diseases; Neurodegenerative disorders; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
  • Discontinued Transplant rejection; Type 1 diabetes mellitus

Most Recent Events

  • 24 Sep 2018 The US FDA approves IND application for foralumab in Neurodegenrerative disorders
  • 24 Sep 2018 Tiziana Life Sciences plans a first-in-human phase I trial for Neurodegenerative disorders in USA (Intranasal)
  • 16 Aug 2018 Preclinical trials in Crohn's disease in United Kingdom (PO) (Tiziana Life Sciences Pipeline, August 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top